Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-curcumin for ischemic stroke: effect on clinical signs and serum IL-6
IRCT20091108002680N3Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of curcumin in ischemic stroke (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Change in clinical neurological signs and Change in serum IL-6 levels. Started Apr 2020; status: completed.
02
Drugs
curcumin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on IRCT20091108002680N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091108002680N3.